Uniseed, established in October 2000, is an Australian venture capital firm based in Saint Lucia, focusing on early-stage investments in biotechnology and technology sectors. Initially formed as a $20 million joint venture between the University of Melbourne and the University of Queensland, Uniseed has expanded its partnerships to include the University of New South Wales, the University of Sydney, and CSIRO. The firm has launched multiple funds, with the latest being a $50 million fund initiated in 2015, aimed at leveraging the extensive research capabilities of its partner universities. Uniseed collaborates closely with the commercialization offices of these institutions, providing specialized support and investment for start-ups emerging from their research. With a focus on generating viable start-up companies and enhancing commercialization processes, Uniseed aims to balance financial returns with the advancement of research initiatives. The firm has a proven track record of investments and successful exits, reflecting its commitment to fostering innovation and supporting the Australian research landscape.
Forcite Helmet Systems Pty Ltd, established in 2013 and located in Haymarket, Australia, specializes in the manufacture of smart helmets designed to enhance motorcycle safety. These helmets are equipped with an integrated camera system, navigation capabilities, intercom functionality, and active noise-cancelling technology. The helmets utilize advanced sensor technology and the Forcite Command software platform to provide features such as visual and audio turn-by-turn navigation, automatic dashcam recording, and real-time hazard warnings. By combining lightweight carbon fiber construction with innovative software, Forcite aims to significantly improve rider safety and offer a more connected riding experience.
Ena Respiratory is a biotechnology company based in Melbourne, Australia, founded in 2014. The company focuses on developing innovative solutions for the treatment and prevention of respiratory infections. Ena Respiratory specializes in synthetic Toll-like receptor 2 (TLR2) agonists, which are designed to activate the innate immune system in the respiratory tract. This activation helps to prevent both viral and secondary bacterial infections in the lungs. In addition to its therapeutic innovations, the company also evaluates the effectiveness of vaccines.
Ena Respiratory is a biotechnology company based in Melbourne, Australia, founded in 2014. The company focuses on developing innovative solutions for the treatment and prevention of respiratory infections. Ena Respiratory specializes in synthetic Toll-like receptor 2 (TLR2) agonists, which are designed to activate the innate immune system in the respiratory tract. This activation helps to prevent both viral and secondary bacterial infections in the lungs. In addition to its therapeutic innovations, the company also evaluates the effectiveness of vaccines.
Ena Respiratory is a biotechnology company based in Melbourne, Australia, founded in 2014. The company focuses on developing innovative solutions for the treatment and prevention of respiratory infections. Ena Respiratory specializes in synthetic Toll-like receptor 2 (TLR2) agonists, which are designed to activate the innate immune system in the respiratory tract. This activation helps to prevent both viral and secondary bacterial infections in the lungs. In addition to its therapeutic innovations, the company also evaluates the effectiveness of vaccines.
Wildlife Drones Pty. Ltd., founded in 2016 and based in Macquarie, Australia, specializes in designing and developing advanced animal radio-tracking systems utilizing drones. The company addresses the challenges faced by wildlife researchers in tracking the movements of radio-tagged animals, particularly those that are highly mobile. Traditional ground-based tracking often requires elevated positions, making it labor-intensive and costly, as it may involve using helicopters or planes to receive clear signals. Wildlife Drones' innovative technology enhances the quality and quantity of radio-tracking data by allowing drones to reach greater altitudes. This capability supports a range of applications for wildlife researchers, conservationists, and environmental consultants, including the monitoring of endangered species, tracking invasive species, and locating livestock on remote properties, thereby aiding efforts to minimize environmental impact.
OccuRx Pty. Ltd. is a Melbourne-based biopharmaceutical company focused on developing innovative therapeutic strategies for treating ophthalmic disorders linked to retinal fibrosis and inflammation. Established in 2014, the company has a library of proprietary small-molecule drugs designed to address the unmet clinical needs in ocular therapies, particularly for conditions like diabetic retinopathy and other fibrotic diseases of the retina. These therapeutic approaches aim to enhance visual acuity and prevent vision loss by targeting the growth of abnormal blood vessels and reducing inflammation in retinal neurons. OccuRx's work is supported by funding from prominent investors, including the Medical Research Commercialisation Fund and Brandon Capital Partners.
Morse Micro PTY. LTD. is an Australian company specializing in the design and development of wireless chip technology, particularly focused on Wi-Fi solutions for the Internet of Things (IoT). Founded in 2016 and headquartered in Eveleigh, Australia, the company offers Wi-Fi HaLow, a low-power wireless technology that enables connections up to one kilometer, making it suitable for a variety of applications including home automation, industrial process control, logistics, surveillance systems, and asset management. The company was established by a team of Wi-Fi innovators and is backed by a strong portfolio of intellectual property and patents, facilitating extensive connectivity across the IoT ecosystem. Morse Micro also has offices in China and the United States, enhancing its global reach and capabilities in the wireless technology market.
Agerris Pty Ltd is an Australian company specializing in the development of modular robotics and artificial intelligence solutions for the agriculture sector. Established in 2005 and headquartered in Chippendale, Agerris has its roots in technology from the Australian Centre for Field Robotics at the University of Sydney. The company offers innovative products like Swagbot, an autonomous modular robot that monitors weed issues, detects crops and livestock, and employs computer vision for various agricultural tasks. Additionally, Agerris has developed the Digital Farmhand platform, which enables farm machinery to identify and assess weeds, as well as count fruits, nuts, and livestock. Their solutions cater to a range of applications, including tree and row crop management, intelligent spraying, and livestock monitoring, thereby enhancing farm productivity while promoting environmental sustainability and animal welfare.
Agerris Pty Ltd is an Australian company specializing in the development of modular robotics and artificial intelligence solutions for the agriculture sector. Established in 2005 and headquartered in Chippendale, Agerris has its roots in technology from the Australian Centre for Field Robotics at the University of Sydney. The company offers innovative products like Swagbot, an autonomous modular robot that monitors weed issues, detects crops and livestock, and employs computer vision for various agricultural tasks. Additionally, Agerris has developed the Digital Farmhand platform, which enables farm machinery to identify and assess weeds, as well as count fruits, nuts, and livestock. Their solutions cater to a range of applications, including tree and row crop management, intelligent spraying, and livestock monitoring, thereby enhancing farm productivity while promoting environmental sustainability and animal welfare.
Forcite Helmet Systems Pty Ltd, established in 2013 and located in Haymarket, Australia, specializes in the manufacture of smart helmets designed to enhance motorcycle safety. These helmets are equipped with an integrated camera system, navigation capabilities, intercom functionality, and active noise-cancelling technology. The helmets utilize advanced sensor technology and the Forcite Command software platform to provide features such as visual and audio turn-by-turn navigation, automatic dashcam recording, and real-time hazard warnings. By combining lightweight carbon fiber construction with innovative software, Forcite aims to significantly improve rider safety and offer a more connected riding experience.
Forcite Helmet Systems Pty Ltd, established in 2013 and located in Haymarket, Australia, specializes in the manufacture of smart helmets designed to enhance motorcycle safety. These helmets are equipped with an integrated camera system, navigation capabilities, intercom functionality, and active noise-cancelling technology. The helmets utilize advanced sensor technology and the Forcite Command software platform to provide features such as visual and audio turn-by-turn navigation, automatic dashcam recording, and real-time hazard warnings. By combining lightweight carbon fiber construction with innovative software, Forcite aims to significantly improve rider safety and offer a more connected riding experience.
Wildlife Drones Pty. Ltd., founded in 2016 and based in Macquarie, Australia, specializes in designing and developing advanced animal radio-tracking systems utilizing drones. The company addresses the challenges faced by wildlife researchers in tracking the movements of radio-tagged animals, particularly those that are highly mobile. Traditional ground-based tracking often requires elevated positions, making it labor-intensive and costly, as it may involve using helicopters or planes to receive clear signals. Wildlife Drones' innovative technology enhances the quality and quantity of radio-tracking data by allowing drones to reach greater altitudes. This capability supports a range of applications for wildlife researchers, conservationists, and environmental consultants, including the monitoring of endangered species, tracking invasive species, and locating livestock on remote properties, thereby aiding efforts to minimize environmental impact.
PERKii Pty Ltd is an Australian company based in Saint Lucia that specializes in producing probiotic beverages. Founded in 2015, PERKii offers a unique drink composed of 85% water, natural flavors, and juice, available in five flavors: Raspberry & Pomegranate, Elderflower & Green Tea, Lime & Coconut, Strawberry & Watermelon, and Mango & Passionfruit. The beverage features Progel™ technology, developed by scientists at The University of Queensland, which encapsulates live probiotics in microgels, allowing them to survive the acidic environment of the stomach and effectively reach the lower digestive system. With only 26 calories and minimal sugar, PERKii aims to promote gut health and support immunity, making it a refreshing choice for health-conscious consumers. The products are sold through various retail and online channels.
Exonate Limited is a private biotech company based in Duxford, United Kingdom, specializing in the discovery and development of small molecule drugs aimed at modulating alternative messenger RNA splicing for ophthalmological applications. Founded in 2013, the company emerged from the University of Nottingham and is focused on addressing retinal vascular diseases, particularly diabetic macular oedema (DMO) and wet age-related macular degeneration (wAMD). Exonate's lead program utilizes small molecule inhibitors that selectively target serine/threonine-protein kinase 1 to inhibit the production of pro-angiogenic vascular endothelial growth factor (VEGF) splice variants. This innovative approach aims to improve therapeutic outcomes and offers a potential alternative to current treatment methods, such as anti-VEGF injections and laser surgery. With a preclinical candidate drug already nominated, Exonate is advancing its research through regulatory toxicology and safety pharmacology studies to facilitate clinical evaluation. The company is backed by an experienced management team with expertise in medicine and drug development.
Q-Sera technology aims to accelerate the clotting of blood to more rapidly produce high quality serum in blood clotting tubes. Q-Sera Pty Ltd uses the coagulant properties of snake venom-derived proteins to develop blood collection tubes that rapidly produce high quality serum. Australian scientists have found a way to use components of snake venom to improve an essential clinical tool which will assist in optimising laboratory efficiency, clinical diagnosis and patient care. The venom of some snakes (including the Australian Taipan) has a potent ability to coagulate the blood of mammals including humans and it is this ability which caught the interest of a group of Queensland medical scientists and pathologists. The team isolated the potent clotting proteins and used them to develop superior blood collection tubes.
Kinoxis Therapeutics is an early-stage biotechnology company based in Australia focused on developing novel therapeutic compounds for substance use disorders and other central nervous system conditions. The company has licensed its lead candidate, which has shown significant anti-addictive and prosocial effects in various animal models, from the University of Sydney. As it advances through pre-clinical testing, Kinoxis aims to address the growing need for effective treatments for opioid withdrawal and other substance-related issues. Their comprehensive medicinal chemistry and screening programs are designed to support the treatment of methamphetamine use disorder and nicotine withdrawal, ultimately contributing to improved outcomes in neurological and psychiatric care.
Nexgen Plants is an emerging plant trait company focused on developing non-genetically modified solutions for various agricultural challenges. The company specializes in creating disease-resistant plant breeds by utilizing a proprietary transformation technique that identifies and harnesses key components in native DNA. This approach aims to produce crops that are resistant to viruses and fungi, as well as those that exhibit beneficial traits like salt tolerance and high anthocyanin content. Nexgen's innovations cater to agriculture-dependent communities, enhancing crop returns and enabling rapid responses to evolving agricultural needs. Their developments are intended to contribute to the next generation of valuable crops for food, fiber, energy, and ornamental purposes.
Developer of an operational management platform designed to help with third-party workflow optimization. The company's platform helps to monitor supplier lifecycle management to the customer and partner validation, enabling businesses to manage risk, compliance, and operations of all third parties globally in one place.
Kinoxis Therapeutics is an early-stage biotechnology company based in Australia focused on developing novel therapeutic compounds for substance use disorders and other central nervous system conditions. The company has licensed its lead candidate, which has shown significant anti-addictive and prosocial effects in various animal models, from the University of Sydney. As it advances through pre-clinical testing, Kinoxis aims to address the growing need for effective treatments for opioid withdrawal and other substance-related issues. Their comprehensive medicinal chemistry and screening programs are designed to support the treatment of methamphetamine use disorder and nicotine withdrawal, ultimately contributing to improved outcomes in neurological and psychiatric care.
Kinoxis Therapeutics is an early-stage biotechnology company based in Australia focused on developing novel therapeutic compounds for substance use disorders and other central nervous system conditions. The company has licensed its lead candidate, which has shown significant anti-addictive and prosocial effects in various animal models, from the University of Sydney. As it advances through pre-clinical testing, Kinoxis aims to address the growing need for effective treatments for opioid withdrawal and other substance-related issues. Their comprehensive medicinal chemistry and screening programs are designed to support the treatment of methamphetamine use disorder and nicotine withdrawal, ultimately contributing to improved outcomes in neurological and psychiatric care.
Cardihab provides clinicians with the ability to remotely deliver a scientifically validated, comprehensive Phase 2 CR program based on ACRA guidelines. In a world first randomised controlled trial, CSIRO & Queensland Health researchers demonstrated that remote delivery of CR improves patient uptake (+29%), adherence (+38%) and completion (+70%) while significantly reducing the number of centre visits (-86%) and delivering equivalent clinical outcomes when compared to traditional, centre-based Phase 2 rehab program.
Cardihab provides clinicians with the ability to remotely deliver a scientifically validated, comprehensive Phase 2 CR program based on ACRA guidelines. In a world first randomised controlled trial, CSIRO & Queensland Health researchers demonstrated that remote delivery of CR improves patient uptake (+29%), adherence (+38%) and completion (+70%) while significantly reducing the number of centre visits (-86%) and delivering equivalent clinical outcomes when compared to traditional, centre-based Phase 2 rehab program.
Brisbane Materials aims to be the leading supplier of anti-reflective and anti-soiling coatings for solar and other applications. Born out of the University of Queensland in 2005, Brisbane Materials builds on six years and significant investment in technology and application experience. Longer term, Brisbane Materials will extend its unique room temperature and atmospheric pressure synthesis of glass and ceramic coatings to a wide variety of materials systems and applications.
QUE Oncology, Inc. is a biotechnology company based in Atlanta, Georgia, founded in 2013 through a collaboration between Emory University and The University of Queensland's research commercialization company, UniQuest. The company focuses on developing innovative drug therapies for cancer, particularly breast and prostate cancer, by licensing intellectual property from both institutions. QUE's leading drug candidate, Q-122, is currently in Phase 1b clinical development and targets hot flashes in women undergoing anti-estrogen therapy for breast cancer. This compound is a non-hormonal, orally bioavailable small molecule designed to alleviate moderate to severe vasomotor symptoms, including night sweats. QUE Oncology's research pipeline also encompasses projects related to prostate cancer, melanoma, and cancer pain, aiming to meet significant unmet medical needs in oncology.
Ena Respiratory is a biotechnology company based in Melbourne, Australia, founded in 2014. The company focuses on developing innovative solutions for the treatment and prevention of respiratory infections. Ena Respiratory specializes in synthetic Toll-like receptor 2 (TLR2) agonists, which are designed to activate the innate immune system in the respiratory tract. This activation helps to prevent both viral and secondary bacterial infections in the lungs. In addition to its therapeutic innovations, the company also evaluates the effectiveness of vaccines.
Smart Sparrow is an education technology company that operates an online learning platform designed for the creation of interactive and adaptive e-learning courseware. Founded in 2010 and headquartered in Surry Hills, Australia, with an additional office in San Francisco, the platform provides intuitive authoring tools that enable students and professionals to develop course materials across a wide range of subjects, including digital literacy, computer sciences, engineering, finance, marketing, medicine, and soft skills. The platform features a dynamic, drag-and-drop interface, allowing educators to design personalized learning paths, collaborate in real time, and utilize pre-made templates to streamline the course development process. Smart Sparrow serves various educational institutions both locally and internationally, and as of December 2019, it operates as a subsidiary of Pearson plc.
Smart Sparrow is an education technology company that operates an online learning platform designed for the creation of interactive and adaptive e-learning courseware. Founded in 2010 and headquartered in Surry Hills, Australia, with an additional office in San Francisco, the platform provides intuitive authoring tools that enable students and professionals to develop course materials across a wide range of subjects, including digital literacy, computer sciences, engineering, finance, marketing, medicine, and soft skills. The platform features a dynamic, drag-and-drop interface, allowing educators to design personalized learning paths, collaborate in real time, and utilize pre-made templates to streamline the course development process. Smart Sparrow serves various educational institutions both locally and internationally, and as of December 2019, it operates as a subsidiary of Pearson plc.
Exonate Limited is a private biotech company based in Duxford, United Kingdom, specializing in the discovery and development of small molecule drugs aimed at modulating alternative messenger RNA splicing for ophthalmological applications. Founded in 2013, the company emerged from the University of Nottingham and is focused on addressing retinal vascular diseases, particularly diabetic macular oedema (DMO) and wet age-related macular degeneration (wAMD). Exonate's lead program utilizes small molecule inhibitors that selectively target serine/threonine-protein kinase 1 to inhibit the production of pro-angiogenic vascular endothelial growth factor (VEGF) splice variants. This innovative approach aims to improve therapeutic outcomes and offers a potential alternative to current treatment methods, such as anti-VEGF injections and laser surgery. With a preclinical candidate drug already nominated, Exonate is advancing its research through regulatory toxicology and safety pharmacology studies to facilitate clinical evaluation. The company is backed by an experienced management team with expertise in medicine and drug development.
PERKii Pty Ltd is an Australian company based in Saint Lucia that specializes in producing probiotic beverages. Founded in 2015, PERKii offers a unique drink composed of 85% water, natural flavors, and juice, available in five flavors: Raspberry & Pomegranate, Elderflower & Green Tea, Lime & Coconut, Strawberry & Watermelon, and Mango & Passionfruit. The beverage features Progel™ technology, developed by scientists at The University of Queensland, which encapsulates live probiotics in microgels, allowing them to survive the acidic environment of the stomach and effectively reach the lower digestive system. With only 26 calories and minimal sugar, PERKii aims to promote gut health and support immunity, making it a refreshing choice for health-conscious consumers. The products are sold through various retail and online channels.
MetaBloQ Pty Ltd is a biotechnology company based in Melbourne, Australia, specializing in the development of innovative drugs aimed at treating challenging cancers, including triple-negative breast cancer, prostate cancer, and melanoma. Founded in 2016, the company focuses on discovering and developing therapies that target specific metabolic processes within cancer cells, with the goal of minimizing toxicity to non-cancerous cells. Through its research and development efforts, MetaBloQ aims to provide patients with safer and more effective treatment options, enhancing their overall quality of life during cancer therapy.
OccuRx Pty. Ltd. is a Melbourne-based biopharmaceutical company focused on developing innovative therapeutic strategies for treating ophthalmic disorders linked to retinal fibrosis and inflammation. Established in 2014, the company has a library of proprietary small-molecule drugs designed to address the unmet clinical needs in ocular therapies, particularly for conditions like diabetic retinopathy and other fibrotic diseases of the retina. These therapeutic approaches aim to enhance visual acuity and prevent vision loss by targeting the growth of abnormal blood vessels and reducing inflammation in retinal neurons. OccuRx's work is supported by funding from prominent investors, including the Medical Research Commercialisation Fund and Brandon Capital Partners.
ProGel Pty Ltd, founded in 2009 and based in Brisbane, Australia, specializes in the development and manufacture of innovative microencapsulation technology. The company emerged from research at the University of Queensland, focusing on a method that allows for the encapsulation of active ingredients for use in foods, cosmetics, and pharmaceuticals. ProGel's calcium alginate microgels are designed to withstand gastric conditions, enabling the effective delivery of high-value additives in functional foods like probiotic drinks and omega-3 enriched products. This technology not only ensures that the encapsulated ingredients remain undetectable to consumers but also provides a cost-effective solution for manufacturers. ProGel is positioned to tap into rapidly growing multi-billion dollar markets, with targeted sectors experiencing growth rates exceeding 10% annually.
Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.
Hatchtech Pty Limited is an Australian specialty pharmaceutical company based in Camberwell, focused on developing innovative treatments for head lice infestations. Established in 2001, it has created Xeglyze, a topical lotion designed to effectively eliminate head lice and their eggs in a single application. The company utilizes a proprietary technology platform that blocks the hatching of pest species eggs through a novel mechanism, allowing for the development of low-toxicity pest control products. This technology not only targets ectoparasites like head lice but also has potential applications for controlling other egg-laying pests affecting humans, animals, crops, and built environments.
Nexgen Plants is an emerging plant trait company focused on developing non-genetically modified solutions for various agricultural challenges. The company specializes in creating disease-resistant plant breeds by utilizing a proprietary transformation technique that identifies and harnesses key components in native DNA. This approach aims to produce crops that are resistant to viruses and fungi, as well as those that exhibit beneficial traits like salt tolerance and high anthocyanin content. Nexgen's innovations cater to agriculture-dependent communities, enhancing crop returns and enabling rapid responses to evolving agricultural needs. Their developments are intended to contribute to the next generation of valuable crops for food, fiber, energy, and ornamental purposes.
Hydrexia is an Australian company that has successfully designed, built, and tested systems that stores hydrogen in solid form, based on a proprietary magnesium alloy.
Hatchtech Pty Limited is an Australian specialty pharmaceutical company based in Camberwell, focused on developing innovative treatments for head lice infestations. Established in 2001, it has created Xeglyze, a topical lotion designed to effectively eliminate head lice and their eggs in a single application. The company utilizes a proprietary technology platform that blocks the hatching of pest species eggs through a novel mechanism, allowing for the development of low-toxicity pest control products. This technology not only targets ectoparasites like head lice but also has potential applications for controlling other egg-laying pests affecting humans, animals, crops, and built environments.
Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.
Smart Sparrow is an education technology company that operates an online learning platform designed for the creation of interactive and adaptive e-learning courseware. Founded in 2010 and headquartered in Surry Hills, Australia, with an additional office in San Francisco, the platform provides intuitive authoring tools that enable students and professionals to develop course materials across a wide range of subjects, including digital literacy, computer sciences, engineering, finance, marketing, medicine, and soft skills. The platform features a dynamic, drag-and-drop interface, allowing educators to design personalized learning paths, collaborate in real time, and utilize pre-made templates to streamline the course development process. Smart Sparrow serves various educational institutions both locally and internationally, and as of December 2019, it operates as a subsidiary of Pearson plc.
Otifex Therapeutics Pty Ltd is an Australian specialty pharmaceutical company focused on developing innovative treatments for Otitis Media with Effusion (OME), a common cause of acquired hearing loss in children. Currently, the standard treatment for OME often involves surgical insertion of grommets to regulate middle ear pressure, with no effective non-invasive alternatives available. Otifex is pioneering a novel nasal spray aimed at facilitating the natural equalization of middle ear pressure, potentially allowing OME to resolve without surgery. The company also produces nasal spray products and tablets based on betahistine, which is known for its use in treating Meniere's Disease and Vestibular Vertigo. These formulations are designed to aid in the clearance of fluid from the middle ear, offering a promising solution for children suffering from OME.
Hatchtech Pty Limited is an Australian specialty pharmaceutical company based in Camberwell, focused on developing innovative treatments for head lice infestations. Established in 2001, it has created Xeglyze, a topical lotion designed to effectively eliminate head lice and their eggs in a single application. The company utilizes a proprietary technology platform that blocks the hatching of pest species eggs through a novel mechanism, allowing for the development of low-toxicity pest control products. This technology not only targets ectoparasites like head lice but also has potential applications for controlling other egg-laying pests affecting humans, animals, crops, and built environments.
BT Imaging Pty Ltd specializes in providing advanced inspection solutions for the photovoltaic manufacturing industry, focusing on silicon blocks, wafers, and solar cells. The company's product line includes the LIS-R3, a leading tool for research laboratories, and the versatile LIS-R2-Plus, designed for research and quality control applications. Additionally, BT Imaging offers various software upgrade packages that enhance measurement capabilities and defect detection across different types of silicon wafers. Their solutions support manufacturers in improving production efficiency and solar cell performance through luminescence-based inspection systems. Established in 2007 and headquartered in Waterloo, Australia, BT Imaging distributes its products globally, serving clients in key markets such as China, Taiwan, Japan, South Korea, Europe, Ireland, Great Britain, and the United States.
ProGel Pty Ltd, founded in 2009 and based in Brisbane, Australia, specializes in the development and manufacture of innovative microencapsulation technology. The company emerged from research at the University of Queensland, focusing on a method that allows for the encapsulation of active ingredients for use in foods, cosmetics, and pharmaceuticals. ProGel's calcium alginate microgels are designed to withstand gastric conditions, enabling the effective delivery of high-value additives in functional foods like probiotic drinks and omega-3 enriched products. This technology not only ensures that the encapsulated ingredients remain undetectable to consumers but also provides a cost-effective solution for manufacturers. ProGel is positioned to tap into rapidly growing multi-billion dollar markets, with targeted sectors experiencing growth rates exceeding 10% annually.
Manjrasoft Pty. Ltd. is a Melbourne-based company that specializes in commercializing grid and cloud computing software technologies developed by the Grid Computing and Distributed Systems Laboratory. Founded in 2008, the company provides Aneka, a platform designed for rapid application development and workload distribution, which enhances the performance of software applications requiring high computational power. Manjrasoft offers various solutions, including distributed 3D rendering using Autodesk Maya, educational and training tools, and cloud computing consultancy services. The company serves diverse sectors such as engineering, entertainment, gaming, life sciences, and finance, enabling organizations to efficiently build, accelerate, and manage their applications and cloud environments.
Fibrotech Therapeutics develops and offers novel drug candidates for the treatment of fibrosis in chronic conditions. It develops drugs for kidney diseases, diabetics, heart failure, pulmonary fibrosis, and arthritis. Founded in 2006, Fibrotech Therapeutics is based in Wonga Park, Australia.
BT Imaging Pty Ltd specializes in providing advanced inspection solutions for the photovoltaic manufacturing industry, focusing on silicon blocks, wafers, and solar cells. The company's product line includes the LIS-R3, a leading tool for research laboratories, and the versatile LIS-R2-Plus, designed for research and quality control applications. Additionally, BT Imaging offers various software upgrade packages that enhance measurement capabilities and defect detection across different types of silicon wafers. Their solutions support manufacturers in improving production efficiency and solar cell performance through luminescence-based inspection systems. Established in 2007 and headquartered in Waterloo, Australia, BT Imaging distributes its products globally, serving clients in key markets such as China, Taiwan, Japan, South Korea, Europe, Ireland, Great Britain, and the United States.
Pepfactants
Series B in 2007
Pepfactants has developed a new way to break apart industrial emulsions, including those found in oil & gas operations, environmental remediation and other manufacturing processes. The company has discovered a chemical additive for demulsify the emulsions, where the additive is cheaper than many alternatives, and withstands extreme levels of salt and other contaminants. The chemical is readily available today as it is used for other, unrelated applications.
Fultec Semiconductor is a circuit protection semiconductor company based in Mountain View, California, founded in 2001. It specializes in transient blocking devices designed to safeguard telecommunication and data communication systems from over-voltage and over-current. The company's products provide wide bandwidth circuit protection against various threats such as lightning, power induction, power cross, and short circuit events. Fultec's solutions cater to a range of applications including telecommunications, data communications, sensors, automotive, and power distribution. As of October 2008, Fultec Semiconductor operates as a subsidiary of Bourns, Inc.
OPAL Therapeutics
Series A in 2005
OPAL Therapeutics Pty Limited operates as an immunotherapy development company in Australia. It develops therapies for the treatment of human immunodeficiency virus, Hepatitis C, and chronic infection. OPAL Therapeutics Pty Limited was incorporated in 2005 and is based in Melbourne, Australia.
Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.
Hatchtech Pty Limited is an Australian specialty pharmaceutical company based in Camberwell, focused on developing innovative treatments for head lice infestations. Established in 2001, it has created Xeglyze, a topical lotion designed to effectively eliminate head lice and their eggs in a single application. The company utilizes a proprietary technology platform that blocks the hatching of pest species eggs through a novel mechanism, allowing for the development of low-toxicity pest control products. This technology not only targets ectoparasites like head lice but also has potential applications for controlling other egg-laying pests affecting humans, animals, crops, and built environments.
QRxPharma Limited is an Australian pharmaceutical company focused on the development and commercialization of innovative pain management and abuse prevention products. Based in Camberwell, Australia, the company emphasizes enhancing the clinical utility of existing compounds while introducing new solutions to the market. Its product portfolio includes both late and early-stage drug candidates, particularly the immediate release MOXDUO®, a dual opioid formulation combining morphine and oxycodone, aimed at treating acute pain. QRxPharma also features Stealth Beadlets™, a proprietary abuse-deterrent technology applicable to solid dosage forms. The company has established strategic partnerships for the commercialization of MOXDUO in various regions, including the United States, Canada, Australia, and South Africa. Additionally, it is collaborating with Aesica Formulation Development Limited to promote its abuse deterrence technology. While QRxPharma has faced challenges in its operations, it remains committed to advancing its product pipeline and improving patient outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.